Molbio Diagnostics Ltd approves Q2 and H1 FY2027 results; CMO Dr. Kuldeep Singh Sachdeva to resign
- Results for the quarter and half year ended September 30, 2026, received an unmodified limited-review conclusion from the statutory auditor; figures were not provided in the announcement.
- Dr. Sachdeva’s resignation is effective January 21, 2027.
- Rakesh Hulihalli & Associates was appointed Secretarial Auditor for FY2026-27 to FY2030-31, subject to shareholder approval; the board also approved the IPO-proceeds monitoring report and a postal ballot with remote e-voting.